Panipenem/betamipron
| Combination of | |
|---|---|
| Panipenem | Carbapenem antibiotic |
| Betamipron | Inhibitor of renal panipenem uptake |
| Clinical data | |
| Trade names | Carbenin |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intravenous |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
Panipenem/betamipron is a carbapenem antibiotic[1] marketed by Daiichi Sankyo Co. of Japan. It was launched in 1993,[2] under the brand name Carbenin.[3]
It is a combination in which panipenem is the carbapenem antibiotic and betamipron inhibits renal uptake of panipenem[4] and so reduces its nephrotoxicity[5] (much like the imipenem/cilastatin combination).
References
[edit]- ^ Hikida M, Terashima S, Sato Y, Okamoato R, Inoue M (November 2001). "[Comparative antibacterial activity of carbapenems against P. aeruginosa (1)]". The Japanese Journal of Antibiotics. 54 (11): 571–9. doi:10.11553/antibiotics1968b.54.571. PMID 11828603.
- ^ "Sankyo Launch". The Pharmaletter. 1994-01-24.
- ^ International Drug Names: Carbenin.
- ^ Finch RG (2003). Antibiotic and chemotherapy: anti-infective agents and their use in therapy. Elsevier Health Sciences. pp. 269ff. ISBN 978-0-443-07129-4. Retrieved 8 August 2011.
- ^ Goa KL, Noble S (2003). "Panipenem/betamipron". Drugs. 63 (9): 913–25, discussion 926. doi:10.2165/00003495-200363090-00005. PMID 12678575. S2CID 263994230.
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |